Chronic obstructive pulmonary disease and inflammatory biomarkers in retired workers exposed to inorganic dusts

  • Joo Hwan Hwang
  • Jin-Ha Yoon
  • JaeHoon Shin
  • Byung-Soon Choi
  • You Lim Lee
  • Jong Sung Lee
  • Kyung Myung Lee
Research article

Abstract

The persistent lung inflammation results in inhaled toxic dusts bring pathologic changes in airway system that lead to development of chronic obstructive pulmonary disease (COPD). Recently, beyond local inflammation in lung, COPD is regarded as chronic systemic inflammatory disease linked to extra pulmonary disease. Therefore, several local and systemic inflammatory biomarkers were needed to be investigated for understanding of COPD. Hence, this current study was aimed to identify the association between COPD and inflammatory biomarkers in workers exposed to inorganic dusts. Clara cell secretary proteins (CC-16) and surfactant protein D (SP-D) were chosen as local inflammatory biomarker, high sensitive Creactive protein (hsCRP), interleukin (IL)-6, serum amyloid protein A (SAA) and tyrosine lysine leucine 40 (YKL-40) were chosen as systemic inflammatory markers in 39 COPD and 39 control group. In current study, CC-16, hsCRP and YKL-40 were linked to COPD in conditional logistic regression model. Furthermore, CC-16 and hsCRP are related to COPD independently to working duration and smoking history. These results suggest that local and inflammatory biomarker could be independent predictor of COPD in worker exposed to inorganic dusts.

Keywords

COPD Inflammatory biomarker Inorganic dusts 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hnizdo, E. & Vallyathan, V. Chronic obstructive pulmonary disease due to occupational exposure to silica dust: a review of epidemiological and pathological evidence. Occup. Environ. Med. 60, 237–243 (2003).PubMedCrossRefGoogle Scholar
  2. 2.
    Bergdahl, I. A. et al. Increased mortality in COPD among construction workers exposed to inorganic dust. Eur. Respir. J. 23, 402–406 (2004).PubMedCrossRefGoogle Scholar
  3. 3.
    Rabe, K. F. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007).PubMedCrossRefGoogle Scholar
  4. 4.
    van Eeden, S. F. & Sin, D. D. Chronic obstructive pul-Chronic Obstructive Pulmonary Disease and Inflammatory Biomarkers 89 monary disease: a chronic systemic inflammatory disease. Respiration 75, 224–238 (2008).Google Scholar
  5. 5.
    Jones, P. W. & Agusti, A. G. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur. Respir. J. 27, 822–832 (2006).PubMedCrossRefGoogle Scholar
  6. 6.
    Kelly, E., Owen, C. A., Pinto-Plata, V. & Celli, B. R. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 7, 57–64 (2013).PubMedCrossRefGoogle Scholar
  7. 7.
    Braido, F. et al. Clara cell 16 protein in COPD sputum: a marker of small airways damage? Respir. Med. 101, 2119–2124 (2007).PubMedCrossRefGoogle Scholar
  8. 8.
    Lomas, D. A. et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 63, 1058–1063 (2008).PubMedCrossRefGoogle Scholar
  9. 9.
    Agusti, A. et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 7, e37483 (2012).PubMedCrossRefGoogle Scholar
  10. 10.
    He, J. Q. et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax 64, 698–704 (2009).Google Scholar
  11. 11.
    Nillawar, A. N., Bardapurkar, J. S. & Bardapurkar, S. J. High sensitive C-reactive protein as a systemic inflammatory marker and LDH-3 isoenzyme in chronic obstructive pulmonary disease. Lung India 29, 24–29 (2012).Google Scholar
  12. 12.
    Korfhagen, T. R. et al. Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo. J. Biol. Chem. 273, 28438–28443 (1998).PubMedCrossRefGoogle Scholar
  13. 13.
    Barnes, P. J. et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174, 6–14 (2006).PubMedCrossRefGoogle Scholar
  14. 14.
    Stockley, R. A. Biomarkers in COPD: time for a deep breath. Thorax 62, 657–660 (2007).PubMedCrossRefGoogle Scholar
  15. 15.
    Umland, T. C. et al. Structure of a human Clara cell phospholipid-binding protein-ligand complex at 1.9 A resolution. Nat. Struct. Mol. Biol. 1, 538–545 (1994).CrossRefGoogle Scholar
  16. 16.
    Yoneda, K. Ultrastructural localization of phospholipases in the Clara cell of the rat bronchiole. Am. J. Pathol. 93, 745–752 (1978).PubMedGoogle Scholar
  17. 17.
    Van Vyve, T. et al. Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects. J. Allergy Clin. 95, 60–68 (1995).CrossRefGoogle Scholar
  18. 18.
    Mattsson, J., Remberger, M., Andersson, O., Sundberg, B. & Nord, M. Decreased serum levels of clara cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early diagnosis in patients after allogeneic stem-cell transplantation. Transplantation 79, 1411–1416 (2005).Google Scholar
  19. 19.
    Shijubo, N. et al. Clara cell protein-positive epithelial cells are reduced in small airways of asthmatics. Am. J. Respir. Crit. Care Med. 160, 930–933 (1999).PubMedCrossRefGoogle Scholar
  20. 20.
    Bernard, A., Marchandise, F. X., Depelchin, S., Lauwerys, R. & Sibille, Y. Clara cell protein in serum and bronchoalveolar lavage. Eur. Respir. J. 5, 1231–1238 (1992).PubMedGoogle Scholar
  21. 21.
    Pilette, C. et al. Reduced epithelial expression of secretory component in small airways correlates with airflow obstruction in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163, 185–194 (2001).PubMedCrossRefGoogle Scholar
  22. 22.
    Honda, Y. et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am. J. Respir. Crit. Care Med. 152, 1860–1866 (1995).PubMedCrossRefGoogle Scholar
  23. 23.
    Ohnishi, H. et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am. J. Respir. Crit. Care Med. 165, 378–381 (2002).PubMedCrossRefGoogle Scholar
  24. 24.
    Lomas, D. A. et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur. Respir. J. 34, 95–102 (2009).PubMedCrossRefGoogle Scholar
  25. 25.
    Winkler, C. et al. Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD. Respir. Res. 12, 29 (2011).PubMedCrossRefGoogle Scholar
  26. 26.
    Yildiz, F., Basyigit, I., Yildirim, E., Boyaci, H. & Ilgazli, A. Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD? Respirology 9, 352–355 (2004).PubMedCrossRefGoogle Scholar
  27. 27.
    Pommer, P. [Peer-reviewed study: COPD — increases risk of pneumonia in early steroid therapy]. Pneumologie 64, 720 (2010).PubMedCrossRefGoogle Scholar
  28. 28.
    Akl, E. A., Grant, B. J., Guyatt, G. H., Montori, V. M. & Schunemann, H. J. A decision aid for COPD patients considering inhaled steroid therapy: development and before and after pilot testing. BMC medical informatics and decision making 7, 12 (2007).PubMedCrossRefGoogle Scholar
  29. 29.
    Cano, N. J. et al. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 126, 540–546 (2004).PubMedCrossRefGoogle Scholar
  30. 30.
    Dev, D. et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir. Med. 92, 664–667 (1998).PubMedCrossRefGoogle Scholar
  31. 31.
    Sin, D. D., Lacy, P., York, E. & Man, S. F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170, 760–765 (2004).PubMedCrossRefGoogle Scholar
  32. 32.
    Ridker, P. M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107, 363–369 (2003).PubMedCrossRefGoogle Scholar
  33. 33.
    Hansell, A. L., Walk, J. A. & Soriano, J. B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 22, 809–814 (2003).PubMedCrossRefGoogle Scholar
  34. 34.
    Broekhuizen, R., Wouters, E. F., Creutzberg, E. C. & Schols, A. M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61, 17–22 (2006).PubMedCrossRefGoogle Scholar
  35. 35.
    Bozinovski, S. et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177, 269–278 (2008).PubMedCrossRefGoogle Scholar
  36. 36.
    Sapey, E. & Stockley, R. A. COPD exacerbations. 2: aetiology. Thorax 61, 250–258 (2006).PubMedCrossRefGoogle Scholar
  37. 37.
    Boot, R. G. et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chito-triosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscle. Thromb. Vasc. Biol. 19, 687–694 (1999).CrossRefGoogle Scholar
  38. 38.
    Chupp, G. L. et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 357, 2016–2027 (2007).PubMedCrossRefGoogle Scholar
  39. 39.
    Yoon, J.-H. et al. Association between impaired lung function and coronary artery calcium score in workers exposed to inorganic dust. Toxicol. Environ. Health Sci. 4, 139–142 (2012).CrossRefGoogle Scholar

Copyright information

© Korean Society of Environmental Risk Assessment and Health Science and Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Joo Hwan Hwang
    • 1
  • Jin-Ha Yoon
    • 1
  • JaeHoon Shin
    • 1
  • Byung-Soon Choi
    • 1
  • You Lim Lee
    • 1
  • Jong Sung Lee
    • 1
  • Kyung Myung Lee
    • 2
  1. 1.Occupational Lung Diseases InstituteGyeonggi-doKorea
  2. 2.Forensic DNA CenterNational Forensic ServiceSeoulKorea

Personalised recommendations